Drug, Device, Coding & Clinical Literature Reference for Physicians

Biosimilars are reshaping prescribing economics across immunology and oncology. This review maps the 2026 approvals, interchangeability designations, and the substitution rules physicians navigate at the point of care — from adalimumab’s crowded field to the newest oncology entrants — with practical guidance on switching, patient communication, and payer coverage that determines what actually reaches the pharmacy counter.

A practical framework for sequencing conventional DMARDs, biologics, and biosimilars in rheumatoid arthritis. We cover when to switch, how to taper safely, and what to monitor — plus the shared-decision conversations that keep patients on therapy when a formulary change forces a substitution mid-treatment.

CD19-directed agents have moved from trials into everyday oncology practice. This practitioner’s guide covers mechanism of action, patient eligibility, dosing logistics, and the prolonged cytopenias to watch for during combination therapy in relapsed or refractory DLBCL — with a checklist for coordinating care across the treatment team.